An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Clinical trial NCT02116803 · COMPLETED
Trial details
- NCT number
- NCT02116803
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-28
- Primary completion
- 2016-11-28
- Enrollment
- 12
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.